Dr. Reddy’s Laboratories (RDY) Given News Impact Rating of -0.02

Media coverage about Dr. Reddy’s Laboratories (NYSE:RDY) has been trending somewhat negative on Sunday, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Dr. Reddy’s Laboratories earned a coverage optimism score of -0.02 on Accern’s scale. Accern also gave press coverage about the company an impact score of 44.9277118117777 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

RDY stock traded down $0.90 during trading on Friday, hitting $33.16. 376,483 shares of the stock traded hands, compared to its average volume of 252,948. The company has a market capitalization of $5,498.89, a PE ratio of 35.66 and a beta of 0.24. Dr. Reddy’s Laboratories has a 52-week low of $29.83 and a 52-week high of $42.97. The company has a current ratio of 1.50, a quick ratio of 1.13 and a debt-to-equity ratio of 0.20.

How to Become a New Pot Stock Millionaire

Dr. Reddy’s Laboratories (NYSE:RDY) last released its quarterly earnings results on Thursday, January 25th. The company reported $0.41 earnings per share for the quarter. The firm had revenue of $596.00 million for the quarter. Dr. Reddy’s Laboratories had a net margin of 6.95% and a return on equity of 8.79%. equities research analysts forecast that Dr. Reddy’s Laboratories will post 1.07 EPS for the current year.

A number of brokerages have issued reports on RDY. ValuEngine cut shares of Dr. Reddy’s Laboratories from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. Zacks Investment Research raised shares of Dr. Reddy’s Laboratories from a “sell” rating to a “hold” rating in a report on Tuesday, January 2nd. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $30.51.

WARNING: This story was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.com-unik.info/2018/03/18/dr-reddys-laboratories-rdy-given-news-impact-rating-of-0-02.html.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.

Insider Buying and Selling by Quarter for Dr. Reddy`s Laboratories (NYSE:RDY)

Receive News & Ratings for Dr. Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit